Welcome to our dedicated page for Lifeward Ltd. Ordinary Shares news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward Ltd. Ordinary Shares stock.
Lifeward™, formerly known as ReWalk Robotics Ltd, is a pioneering medical device company dedicated to transforming the lives of individuals with physical limitations and disabilities. Founded in 2001, Lifeward designs, develops, and commercializes innovative solutions that span the continuum of care in physical rehabilitation and recovery. The company's mission is to relentlessly drive innovation, delivering functional and health benefits in clinical settings as well as in the home and community.
Headquartered in the United States, with additional operations in Israel and Germany, Lifeward's product portfolio includes the ReWalk Personal Exoskeleton, ReWalk Rehabilitation Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES systems. These devices empower individuals to achieve their goals through improved mobility and health outcomes.
Lifeward has garnered significant recognition for its life-changing technology, particularly the ReWalk Exoskeleton, which has been crucial for individuals with spinal cord injuries. The company's efforts have been acknowledged by the Centers for Medicare & Medicaid Services (CMS), which has made strides in establishing a reimbursement pathway for the ReWalk Personal Exoskeleton. This development is a significant step toward making this revolutionary technology accessible to more people.
In recent news, Lifeward has unveiled its new branding and expanded its portfolio with the inclusion of AlterG Anti-Gravity systems. The rebranding reflects the company's broader vision and commitment to elevating the standard of care for individuals facing physical limitations. CEO Larry Jasinski stated that the transformation to Lifeward symbolizes their goal to be the driving force in overcoming physical disabilities.
Lifeward operates through markets in the United States and Europe, with additional sales in Asia, the Middle East, and South America. The company's financial health remains robust, as evidenced by their latest financial results and continuous efforts to innovate and expand their market presence. Lifeward's commitment to excellence is further highlighted by partnerships with healthcare providers and legislative efforts to enhance access to their technologies for veterans and other individuals in need.
For more information about Lifeward's mission and product offerings, visit GoLifeward.com.
Lifeward (Nasdaq: LFWD) announced that Hungary has established a new state insurance code providing coverage for ReWalk exoskeleton training for individuals with spinal cord injury. This decision follows research at Semmelweis University's Rehabilitation Clinic in Budapest, which studied the long-term therapeutic benefits of ReWalk Exoskeleton rehabilitation. Hungary joins Germany and the United States in providing coverage for exoskeletons. ReWalk is currently the only exoskeleton with both US FDA and EU CE/MDR certification that can be used at home. Hungary reports approximately 300 new cases of spinal cord injury annually.
Lifeward reported its Q3 2024 financial results, showing significant growth and cost-saving measures.
Revenue increased by 39% to $6.1 million, driven by strong sales of ReWalk systems and AlterG products. The company sold 20 ReWalk systems for the second consecutive quarter and has 70 qualified leads for potential Medicare claims.
Gross margin improved to 36.2%, while operating expenses decreased to $5.4 million. Net loss narrowed to $3.1 million or $0.35 per share, compared to $7.5 million or $0.88 per share in Q3 2023.
Lifeward also initiated actions to streamline U.S. operations, expected to save $3 million in operating expenses. The company launched the AlterG NEO, generating orders for 40 units since June.
As of September 30, Lifeward had $10.7 million in cash with no debt. The company revised its 2024 revenue guidance to $25-$26 million, expecting the highest quarterly revenue in Q4.
Lifeward announced the appointment of Robert J. Marshall Jr. to its Board of Directors, effective November 2, 2024. Mr. Marshall will serve as Chairman of the Audit Committee. He brings over 30 years of experience in financial management and strategy, mainly in the medical device industry. Currently, he is the CFO and Treasurer of Lantheus Holdings. His previous roles include senior leadership positions at Zimmer Biomet Holdings, where he managed finance for U.S., Canadian, and Latin American markets. Marshall expressed his enthusiasm for Lifeward's mission and future in rehabilitation advancements. Lifeward's Chairman, Joe Turk, highlighted Marshall's financial acumen and governance capabilities as significant assets to the Board.
Lifeward (Nasdaq: LFWD) has scheduled its third quarter 2024 financial results release for Tuesday, November 12, 2024, before market open. CEO Larry Jasinski and CFO Michael Lawless will host a conference call and webcast at 8:30 a.m. EST to discuss the results. The earnings call will be accessible via multiple toll-free numbers across different countries and through a webcast link available on the company's website at GoLifeward.com in the Investors section.
Lifeward (NASDAQ: LFWD) announced plans to streamline U.S. operations by closing two facilities as part of its post-AlterG acquisition integration. The consolidation will centralize operations in Massachusetts, Israel, and Germany. Key functions will be integrated into the Marlborough facility, with AlterG Anti-Gravity Systems manufacturing transferred to Cirtronics The company expects $3 million in annual operating expense savings and a 200 basis points improvement in gross margins during 2025. Since the AlterG acquisition, Lifeward has reduced its total headcount by over 35%.
Lifeward (Nasdaq: LFWD), a global leader in rehabilitation and recovery solutions, has announced its participation in the upcoming ThinkEquity Conference. Chief Financial Officer Mike Lawless will deliver a company overview presentation on October 30, 2024, at 3:00 PM EDT. The presentation will be accessible through the company's Investor Relations website and via webcast. Lawless will also conduct one-on-one meetings with investors during the conference. A replay of the presentation will remain available for 90 days after the event.
Lifeward (Nasdaq: LFWD) has announced the launch of direct sales for its AlterG product line in Germany, effective immediately. This strategic move, announced at the REHACARE 2024 conference in Düsseldorf, adds AlterG products to the company's German sales portfolio alongside the ReWalk Personal Exoskeleton.
The company expects several financial benefits from this direct sales approach, including increased revenue due to a more focused sales effort and higher margins with minimal additional investment. Lifeward aims to leverage its existing sales and support infrastructure in Germany to expand market penetration and accelerate its path to profitability both in Germany and globally.
While Lifeward begins direct sales, PHYSIOMED GROUP will continue to provide service and support to its existing base of nearly 500 customers in Germany and distribute AlterG units in parallel with the Lifeward team.
ReWalk Robotics has officially changed its name to Lifeward , completing the rebranding initiative announced on January 29, 2024. The change follows shareholder approval on September 4, 2024, and approval from the Israel Companies Registrar on September 10, 2024. This transformation reflects the company's expanded mission to elevate care standards for overcoming physical limitations and disabilities.
CEO Larry Jasinski stated that the rebranding aligns with Lifeward's goal to empower individuals to pursue their passions despite physical challenges. The company's U.S. and German subsidiaries have already adopted the new name, and the stock will continue trading under the symbol 'LFWD' on Nasdaq. The new name will be effective for trading starting September 13, 2024.
Lifeward (Nasdaq: LFWD) has appointed Dr. Keith E. Tansey as Consulting Director of Clinical Research. With over 30 years of experience in spinal cord injury research and treatment, Dr. Tansey brings valuable expertise to Lifeward's Medical Affairs team. His responsibilities include developing the company's clinical research program, advancing key opinion leader opportunities, and supporting clinical partnerships to expand the use of personal exoskeletons for individuals with spinal cord injuries.
Dr. Tansey, a Professor at the University of Mississippi Medical Center and a Physician Scientist at the Veterans Administration Medical Center, is board-certified in Neurology with subspecialty certifications in Spinal Cord Injury Medicine and Neural Repair and Rehabilitation. His appointment aligns with Lifeward's mission to improve the lives of individuals with physical limitations or disabilities through innovative rehabilitation solutions.
Lifeward (Nasdaq: LFWD) has successfully completed its first ReWalk Step Challenge 2024, a charity initiative involving ReWalk Personal Exoskeleton users in Germany. The challenge resulted in a €5,000 donation to the Association for the Promotion of Paraplegics in Germany (FGQ). Participants collectively achieved 424,844 steps during the one-month challenge, with Lifeward donating one cent per step taken.
The funds will support FGQ's mission to assist people with spinal cord injuries and their families. Lifeward CEO Larry Jasinski expressed satisfaction with the community's engagement and the opportunity to support the European Spinal Cord Injury Federation (ESCIF). The company plans to repeat the challenge next year, aiming for increased participation to further support the paraplegic community.
FAQ
What is the current stock price of Lifeward Ltd. Ordinary Shares (LFWD)?
What is the market cap of Lifeward Ltd. Ordinary Shares (LFWD)?
What is Lifeward?
What products does Lifeward offer?
Where does Lifeward operate?
What recent achievements has Lifeward made?
How does the ReWalk Personal Exoskeleton benefit users?
What is the CMS reimbursement pathway for the ReWalk Personal Exoskeleton?
Who founded Lifeward and when?
What is Lifeward's mission?
How can I learn more about Lifeward's products and mission?
Who should I contact for media or investor relations at Lifeward?
